Heparan Sulfate Proteoglycans Can Promote Opposite Effects on Adhesion and Directional Migration of Different Cancer Cells.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
24 12 2020
Historique:
pubmed: 8 12 2020
medline: 3 2 2021
entrez: 7 12 2020
Statut: ppublish

Résumé

Heparan sulfate proteoglycans take part in crucial events of cancer progression, such as epithelial-mesenchymal transition, cell migration, and cell invasion. Through sulfated groups on their glycosaminoglycan chains, heparan sulfate proteoglycans interact with growth factors, morphogens, chemokines, and extracellular matrix (ECM) proteins. The amount and position of sulfated groups are highly variable, thus allowing differentiated ligand binding and activity of heparan sulfate proteoglycans. This variability and the lack of specific ligands have delayed comprehension of the molecular basis of heparan sulfate proteoglycan functions. Exploiting a tumor-targeting peptide tool that specifically recognizes sulfated glycosaminoglycans, we analyzed the role of membrane heparan sulfate proteoglycans in the adhesion and migration of cancer cell lines. Starting from the observation that the sulfated glycosaminoglycan-specific peptide exerts a different effect on adhesion, migration, and invasiveness of different cancer cell lines, we identified and characterized three cell migration phenotypes, where different syndecans are associated with alternative signaling for directional cell migration.

Identifiants

pubmed: 33284606
doi: 10.1021/acs.jmedchem.0c01848
doi:

Substances chimiques

Glypicans 0
Heparan Sulfate Proteoglycans 0
Syndecans 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15997-16011

Auteurs

Lorenzo Depau (L)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Jlenia Brunetti (J)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Chiara Falciani (C)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Elisabetta Mandarini (E)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Giulia Riolo (G)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Marta Zanchi (M)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Evgenia Karousou (E)

Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy.

Alberto Passi (A)

Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy.

Alessandro Pini (A)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Luisa Bracci (L)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH